Mizoribine: A new approach in the treatment of renal disease

Clinical and Developmental Immunology

Volumn 2009, Issue , 2009, Pages

  Kawasaki, Yukihiko ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; CYTOTOXIC AGENT; DILAZEP; DIPYRIDAMOLE; HEPARIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MITOGENIC AGENT; MIZORIBINE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO; PREDNISOLONE; TACROLIMUS; WARFARIN; INOSINATE DEHYDROGENASE; RIBONUCLEOSIDE;

ALBUMIN BLOOD LEVEL; ALOPECIA; ANCA ASSOCIATED VASCULITIS; ANEMIA; ANOREXIA; ANTIBODY TITER; BONE MARROW SUPPRESSION; CELL CYCLE ARREST; CELL GROWTH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DNA SYNTHESIS INHIBITION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PULSE THERAPY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOCAL GLOMERULOSCLEROSIS; GASTROINTESTINAL SYMPTOM; GRAFT SURVIVAL; GROWTH INHIBITION; HERPES ZOSTER; HUMAN; HYPERURICEMIA; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIVER DYSFUNCTION; LUNG MYCOSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; METABOLITE; MONOTHERAPY; NAUSEA; NEPHROTIC SYNDROME; NONHUMAN; NUCLEIC ACID SYNTHESIS; PLASMAPHERESIS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; PRURIGO; RECOMMENDED DRUG DOSE; RELAPSE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RNA SYNTHESIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MANIFESTATION; STOMATITIS; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; VIRUS INFECTION; VOMITING; ADOLESCENT; ADULT; CHILD; DRUG ANTAGONISM; FEMALE; MIDDLE AGED;

ADOLESCENT; ADULT; CHILD; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KIDNEY DISEASES; LUPUS NEPHRITIS; MIDDLE AGED; NEPHROTIC SYNDROME; RIBONUCLEOSIDES; TREATMENT OUTCOME;

EID: 73449130490     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2009/681482     Document Type: Review

References (40)

1. Mizuno K., Tsujino M., Takada M., Hayashi M., Atsumi K., Studies on bredinin. I. Isolation, characterization and biological properties Journal of Antibiotics 1974 27 10 775 782
2. Kamata K., Okubo M., Ishigamori E., Immunosuppressive effect of bredinin on cell-mediated and humoral immune reactions in experimental animals Transplantation 1983 35 2 144 149
3. Ichikawa Y., Ihara H., Takahara S., The immunosuppressive mode of action of mizoribine Transplantation 1984 38 3 262 267
4. Ishikawa H., Mizoribine and mycophenolate mofetil Current Medicinal Chemistry 1999 6 7 575 597
5. Hamasaki T., Mori M., Kinoshita Y., Saeki T., Sakano T., Mizoribine in steroid-dependent nephrotic syndrome of childhood Pediatric Nephrology 1997 11 5 625 627
6. Sonda K., Takahashi K., Tanabe K., Clinical pharmacokinetic study of mizoribine in renal transplantation patients Transplantation Proceedings 1996 28 6 3643 3648
7. Allison A. C., Hovi T., Watts R. W. E., Webster A. D. B., Immunological observations on patients with Lesch Nyhan syndrome, and on the role of de novo purine synthesis in lymphocyte transformation The Lancet 1975 2 7946 1179 1183
8. Allison A. C., Hovi T., Watts R. W., Webster A. D., The role of de novo purine synthesis in lymphocyte transformation Ciba Foundation Symposium 1977 48 207 224
9. Hovi T., Allison A. C., Raivio K., Vaheri A., Purine metabolism and control of cell proliferation Ciba Foundation Symposium 1977 48 225 248
10. Sakaguchi K., Tsujino M., Yoshizawa M., Mizuno K., Hayano K., Action of bredinin on mammalian cells Cancer Research 1975 35 7 1643 1648
11. Sakaguchi K., Tsujino M., Mizuno K., Hayano K., Ishida N., Effect of bredinin and its aglycone on L5178Y cells Journal of Antibiotics 1975 28 10 798 803
12. LePage G. A., Whitecar J. P. Jr., Pharmacology of 6-thioguanine in man Cancer Research 1971 31 11 1627 1631
13. Sakaguchi K., Tsujino M., Hayashi M., Kawai K., Mizuno K., Hayano K., Mode of action of bredinin with guanylic acid on L5178Y mouse leukemia cells Journal of Antibiotics 1976 29 12 1320 1327
14. Koyama H., Tsuji M., Genetic and biochemical studies on the activation and cytotoxic mechanism of bredinin, a potent inhibitor of purine biosynthesis in mammalian cells Biochemical Pharmacology 1983 32 23 3547 3553
15. Kusumi T., Tsuda M., Katsunuma T., Yamamura M., Dual inhibitory effect of bredinin Cell Biochemistry and Function 1989 7 3 201 204
16. Turka L. A., Dayton J., Sinclair G., Thompson C. B., Mitchell B. S., Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine Journal of Clinical Investigation 1991 87 3 940 948
17. Dayton J. S., Turka L. A., Thompson C. B., Mitchell B. S., Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism Molecular Pharmacology 1992 41 4 671 676
18. Itoh H., Komatsuda A., Wakui H., Miura A. B., Tashima Y., Mammalian HSP60 is a major target for an immunosuppressant mizoribine Journal of Biological Chemistry 1999 274 49 35147 35151
19. Takahashi S., Wakui H., Gustafsson J.-A., Zilliacus J., Itoh H., Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein Biochemical and Biophysical Research Communications 2000 274 1 87 92
20. Murase J., Mizuno K., Kawai K., Absorption, distribution, metabolism and excretion of bredinin in rats Pharmacometrics 1978 15 5 829 835
21. Kusaba R., Otubo O., Inou T., Tsujino M., Ishikawa H., Studies on pharmacokinetics of bredinin Japanese Journal of Transplantation 1982 17 supplement 585
22. Takada K., Muranishi S., Asada S., Clinical pharmacokinetic study of bredinin in renal transplant patients Transplantation 1982 17 supplement 595
23. Stypinski D., Obaidi M., Combs M., Weber M., Stewart A. J., Ishikawa H., Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers British Journal of Clinical Pharmacology 2007 63 4 459 468
24. Kawasaki Y., Suzuki J., Takahashi A., Isome M., Nozawa R., Suzuki H., Mizoribine oral pulse therapy for steroid-dependent nephrotic syndrome Pediatric Nephrology 2005 20 1 96 98
25. Kawasaki Y., Hosoya M., Kobayashi S., Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrome Nephrology Dialysis Transplantation 2005 20 10 2243 2247
26. Kawasaki Y., Takano K., Isome M., Efficacy of single dose of oral mizoribine pulse therapy two times per week for frequently relapsing nephrotic syndrome Journal of Nephrology 2007 20 1 52 56
27. Tanabe K., Tokumoto T., Ishikawa N., Long-term results in mizoribine-treated renal transplant recipients: a prospective, randomized trial of mizoribine and azathioprine under cyclosporine-based immunosuppression Transplantation Proceedings 1999 31 7 2877 2879
28. Kaneko K., Nagaoka R., Ohtomo Y., Yamashiro Y., Mizoribine for childhood IgA nephropathy Nephron 1999 83 4 376 377
29. Nagaoka R., Kaneko K., Ohtomo Y., Yamashiro Y., Mizoribine treatment for childhood IgA nephropathy Pediatrics International 2002 44 2 217 223
30. Kawasaki Y., Suzuki J., Sakai N., Efficacy of prednisolone and mizoribine therapy for diffuse IgA nephropathy American Journal of Nephrology 2004 24 1 147 153
31. Yoshikawa N., Nakanishi K., Ishikura K., Hataya H., Iijima K., Honda M., Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study Pediatric Nephrology 2008 23 5 757 763
32. Koshikawa S., Sato M., Narita M., Sakai N., Nakajima M., Clinical evalution of an immunosuppressive drug, mizoribine (HE-69) on steroid-resistant nephritic syndrome-A multicenter double-blind comparison study with placebo Kidney and Dialysis 1993 34 631
33. Yoshioka K., Ohashi Y., Sakai T., A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome Kidney International 2000 58 1 317 324
34. Ohtomo Y., Fujinaga S.-I., Takada M., High-dose mizoribine therapy for childhood-onset frequently relapsing steroid-dependent nephrotic syndrome with cyclosporin nephrotoxicity Pediatric Nephrology 2005 20 12 1744 1749
35. Yumura W., Suganuma S., Uchida K., Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis Clinical Nephrology 2005 64 1 28 34
36. Tanaka H., Tsugawa K., Suzuki K., Nakahata T., Ito E., Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis Pediatric Nephrology 2006 21 7 962 966
37. Tanaka H., Tsugawa K., Oki E., Suzuki K., Ito E., Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patients Clinical Rheumatology 2008 27 1 85 89
38. Nozu K., Iijima K., Kamioka I., High-dose mizoribine treatment for adolescents with systemic lupus erythematosus Pediatrics International 2006 48 2 152 157
39. Imaizumi T., Kawasaki Y., Matsuura H., Efficacy of steroid pulse, plasmapheresis, and mizoribine in a patient with focal segmental glomerulosclerosis Pediatric Nephrology 2007 22 8 1215 1218
40. Hirayama K., Kobayashi M., Hashimoto Y., Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis American Journal of Kidney Diseases 2004 44 1 57 63